Pediatrics

Search results

• RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia

  Stephen Hunger

  29/06/22

  1 item of Media coverage

  Press/Media

• Xenikos Enrolls First Patient In Global Pivotal Phase 3 Study Evaluating T-Guard® In Patients With Steroid-Refractory Acute Graft-Versus-Host Disease

  John Levine

  27/06/22 → 28/06/22

  2 items of Media coverage

  Press/Media

• Xenikos Enrolls First Patient in Global Pivotal Phase 3 Study Evaluating T-Guard® in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease

  John Levine

  28/06/22

  1 item of Media coverage

  Press/Media

• AbbVie's Risankizumab (Skyrizi) Approved to Treat Moderately to Severely Active Crohn Disease

  Marla Dubinsky

  28/06/22

  1 item of Media coverage

  Press/Media

• Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard® in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

  John Levine

  28/06/22

  6 items of Media coverage

  Press/Media

• Veloxis Pharmaceuticals Announces Dosing Of The First Patient By Partner Xenikos In The Global Phase 3 Study Evaluating T-Guard® In Patients With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-Agvhd)'

  John Levine

  28/06/22

  1 item of Media coverage

  Press/Media

• Xenikos Enrolls First Patient in Global Pivotal Phase 3 Study Evaluating T-Guard® in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease

  John Levine

  27/06/22

  16 items of Media coverage

  Press/Media

• Xenikos Enrolls First Patient In Global Pivotal Phase 3 Study Evaluating T-Guard® In Patients With Steroid-Refractory Acute Graft-Versus-Host Disease

  John Levine

  27/06/22

  1 item of Media coverage

  Press/Media

• AbbVie receives FDA nod for new indication of Skyrizi

  Marla Dubinsky

  27/06/22

  1 item of Media coverage

  Press/Media

• US FDA approves AbbVie's interleukin-23 inhibitor, Skyrizi to treat moderately to severely active Crohn's disease

  Marla Dubinsky

  20/06/22 → 21/06/22

  2 items of Media coverage

  Press/Media

• US FDA approves AbbVie’s interleukin-23 inhibitor, Skyrizi to treat moderately to severely active Crohn's disease

  Marla Dubinsky

  21/06/22

  1 item of Media coverage

  Press/Media

• -SKYRIZI (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults

  Marla Dubinsky

  20/06/22

  3 items of Media coverage

  Press/Media

• Former Bayer Senior Executive Joins Sirona Biochem Advisory Board

  Marla Dubinsky

  20/06/22

  1 item of Media coverage

  Press/Media

• AbbVie (ABBV) Announces SKYRIZI Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults

  Marla Dubinsky

  17/06/22 → 18/06/22

  2 items of Media coverage

  Press/Media

• SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults

  Marla Dubinsky

  17/06/22

  65 items of Media coverage

  Press/Media

• FDA Approves Skyrizi for Patients with Crohn’s Disease

  Marla Dubinsky

  17/06/22

  1 item of Media coverage

  Press/Media

• FDA Appropves Risankizumab For Crohn’s Disease

  Marla Dubinsky

  17/06/22

  2 items of Media coverage

  Press/Media

• Boosh Plant-Based Brands Corporate Update

  Marla Dubinsky

  17/06/22

  2 items of Media coverage

  Press/Media

• Pushing for top spot in Big Pharma, AbbVie lands a key approval for its blockbuster Skyrizi

  Marla Dubinsky

  17/06/22

  1 item of Media coverage

  Press/Media

• Dr. Leonard Barry Smith selected for IAOTP’s Top 50 Fearless Leaders Publication

  Stuart Young

  10/06/22

  2 items of Media coverage

  Press/Media

• Steroid phobia drives weaker prescribing, nonadherence.(PEDIATRIC DERMATOLOGY)

  Nanette Silverberg

  1/06/22

  1 item of Media coverage

  Press/Media

• Lilly boosted by mirikizumab data in UC

  Marla Dubinsky

  25/05/22

  1 item of Media coverage

  Press/Media

• Australian Patent Office Grants Patent for 'Peptides, reagents and methods for detecting food allergy'

  Jing Lin

  20/05/22

  1 item of Media coverage

  Press/Media

• Flint Water Crisis Whistleblower to Speak at College of Medicine Commencement

  Mona Hanna-Attisha

  20/05/22

  1 item of Media coverage

  Press/Media

• - Mount Sinai Appoints Bruce D. Gelb as Dean for Child Health Research

  Bruce Gelb

  19/05/22

  1 item of Media coverage

  Press/Media